彭伟皑’s Post

Last month, professionals and advocates from all of the country gathered at Capitol Hill, we educated and advocated on the impact of three important topics. The first topic was THE FIND ACT. The FIND ACT is now more important than ever as the field of Nuclear Medicine and Molecular Imaging has entered an era of growth furthering the sector of precision medicine. However, due to CMS bundling our specialized isotopes as a "supply", many organizations cannot absorb the financial loss. This has limited access to this care. The organizations that do perform the more specialized imaging, either absorb the cost or switch to the latest radiopharmaceutical coming out for commercial use because of pass through. <---- this in particular is bothersome as we should switch as the radiopharmaceuticals IMPROVE patient outcomes not because CMS establishes a limited reimbursement window. Please follow the link below to send a pre-drafted letter to your state legislators.

Recently The Journal of Nuclear Medicine - JNM published the 6-month interim analysis from the EPIC-Skin study co-authored by GenesisCare clinicians, A/Prof Sid Baxi, Prof Angela Hong, and A/Prof Joe Cardaci. The aim of the interim analysis is to provide an early indication about the efficacy, safety, and associated patient-reported treatment comfort and quality of life outcomes following treatment of BCC and SCC with Rhenium SCT - a novel non-invasive radionuclide radiation therapy, provided in a single-session. To read the article, please click here: https://lnkd.in/eZKikXe5 #SkinCancer #NuclearMedicine #designingbettercare #clinicaltrials

This is extremely important for getting our patient the care and imaging they need that is detrimental for their treatment and planning. Write your legislators today! Don’t have time; they did the work for you! Did it from my phone in less than 30 seconds! #patientcare #accesstocare #supportingpatientneeds #submityoursupport #nuclearmedicine #legislation #timewellspent

First-in-Human Pb-212-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant #Prostatecancer. #research #radiotheranostics #radiopharmaceuticals #PSMA #pb212 The Journal of Nuclear Medicine - JNM

What is theranostics, and why do some researchers think it's the future of cancer diagnosis and treatment? In SNMMI's first feature on Jobs of Tomorrow, learn more about the groundbreaking field of nuclear medicine. View the whole episode, now on our Nuclear Medicine Careers website, here: https://lnkd.in/gr4W92r5 This episode features SNMMI member Carlos Uribe--full ambassador spotlight to come, so stay tuned! #nuclearmedicine #theranostics #cancerresearch #career #careergoals

I’m excited to share that I have completed a workshop titled: "Introduction to Cyclotrons and Their Role in Nuclear Medicine Imaging" presented by Eng. Adel Mannoun from Learnak. Looking forward to applying this new knowledge in the field of nuclear medicine and advanced medical imaging. It was a very enriching and insightful experience! #NuclearMedicine #Cyclotron #MedicalImaging #HealthcareInnovation #Radiopharmaceuticals #ContinuingEducation #MedicalPhysics #NuclearScience #HealthTech #Learnak #Medicine #Imaging

📢𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗲𝘀𝗲 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗶𝗻𝗴 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻𝘀 𝗯𝘆 𝗣𝗗 𝗗𝗿. Marc Pretze 𝗮𝘁 𝗘𝗔𝗡𝗠'𝟮𝟰! 👋 Join us at 𝗯𝗼𝗼𝘁𝗵 𝗛𝟭𝟵 during 𝗘𝗔𝗡𝗠'𝟮𝟰 in Hamburg for 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗤&𝗔 𝘀𝗲𝘀𝘀𝗶𝗼𝗻𝘀 by one of the 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘃𝗼𝗶𝗰𝗲𝘀 𝗶𝗻 𝗮𝗹𝗽𝗵𝗮 𝗲𝗺𝗶𝘁𝘁𝗲𝗿 𝗿𝗮𝗱𝗶𝗼𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆, 𝗣𝗗 𝗗𝗿. 𝗠𝗮𝗿𝗰 𝗣𝗿𝗲𝘁𝘇𝗲! 🌟 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ▶️ 𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗦𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀: Discover the 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 in automating the synthesis of radiopharmaceuticals labeled with alpha emitters. ▶️ 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗖𝗼𝗻𝘁𝗿𝗼𝗹: Learn about the 𝘀𝘁𝗮𝘁𝗲-𝗼𝗳-𝘁𝗵𝗲-𝗮𝗿𝘁 𝗺𝗲𝘁𝗵𝗼𝗱𝘀 in ensuring the 𝗵𝗶𝗴𝗵𝗲𝘀𝘁 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀 𝗼𝗳 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 for these innovative therapies. ▶️ 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: Dr. Pretze will dive into the 𝘂𝗻𝗶𝗾𝘂𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 associated with 𝗮𝗹𝗽𝗵𝗮 𝗲𝗺𝗶𝘁𝘁𝗲𝗿 𝗿𝗮𝗱𝗶𝗼𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 and how his team is 𝘁𝗮𝗰𝗸𝗹𝗶𝗻𝗴 𝘁𝗵𝗲𝘀𝗲 𝗶𝘀𝘀𝘂𝗲𝘀 at the Department of Nuclear Medicine, Universitätsklinikum Carl Gustav Carus Dresden and Technische Universität Dresden. 📅 𝗦𝗮𝘃𝗲 𝘁𝗵𝗲 𝗗𝗮𝘁𝗲! We're looking forward to seeing you all there. Join us in learning more about radiochemistry and 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝘄𝗶𝘁𝗵 𝗮𝗹𝗽𝗵𝗮-𝗹𝗮𝗯𝗲𝗹𝗲𝗱 𝗰𝗼𝗺𝗽𝘂𝗻𝗱𝘀! 📄 Find out more in the 𝗳𝗹𝘆𝗲𝗿 𝗯𝗲𝗹𝗼𝘄 and join us for 𝗳𝗿𝘂𝗶𝘁𝗳𝘂𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀! #Radiochemistry #AlphaEmitters #Radiopharmaceuticals #NuclearMedicine #ContributingToSavingLives

Can AI combined with SPECT/CT myocardial perfusion imaging (MPI) effectively predict hospitalization for acute heart failure? According to a team of U.S. researchers, the answer is yes. A recent study published in The Journal of Nuclear Medicine - JNM represents, to our knowledge, the first evidence demonstrating that integrating SPECT MPI into an AI-based risk assessment algorithm significantly improves the prediction of hospitalizations due to heart failure. You can read more about this interesting breakthrough here: https://lnkd.in/gacjSFEe #NuclearMedicine #Radiopharmaceuticals #HeartHealth

#DidYouKnow in the 2010's, the emergence of radiotherapeutics using isotopes like Lu-177 marked a milestone shift in the nuclear medicine market, changing the importance of isotopes in healthcare? The radiotherapeutic market represented 20% of the total nuclear medicine market in 2019, up from 6% in 2013. Through continued investment and innovation, it is projected that radiotherapeutics will represent around 75% of the market by 2031, massively expanding the possibilities for personalized medical treatments!

The next #ISMERAD symposium takes place on the 26th of April 2024 in Ghent. This edition the focus lies on Alpha Therapy!